Endothelium-targeted pharmacotherapeutics for the treatment of stroke.
The pathophysiology of stroke in humans is much more complex than what is typically studied in animal models. Embolic stroke models are more complex than pure ischemia models, but are more representative of human disease and may be particularly useful in the study of new therapeutic strategies. Vascular damage is a prominent feature of embolic stroke, and may be a useful therapeutic target. Serotonin antagonists, adenosine-regulating agents, free radical scavengers, matrix metalloproteinase inhibitors, and HMG-CoA reductase inhibitors are all potentially valuable agents in treating vascular damage after stroke. These agents facilitate decreased infarction volume, hemorrhage, and improved cerebral bloodflow.
Danton
Gary
G
Watson
Brant D
BD
Prado
Ricardo
R
Dietric
W Dalton
WD
D000241:Adenosine / Q000819:agonists; D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy / Q000378:metabolism; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000187:drug effects*; D016166:Free Radical Scavengers / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D061965:Matrix Metalloproteinase Inhibitors; D012702:Serotonin Antagonists / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy* / Q000378:metabolism; D014665:Vasodilator Agents / Q000627:therapeutic use*
D016166:Free Radical Scavengers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D061965:Matrix Metalloproteinase Inhibitors; D012702:Serotonin Antagonists; D014665:Vasodilator Agents; D000241:Adenosine